Angus Dalgleish trained at University College Hospital, where he also did an intercalated degree in anatomy with Professor J. Z. Young. Following house jobs, he took a position with the Flying Doctor Service in Australia for one year, and stayed on to train in internal medicine and oncology at hospitals in Brisbane and Sydney.
He returned to the U.K. in 1984, and undertook a thesis on retroviruses with Robert Weiss. He was then appointed as Senior Clinical Scientist at the MRC Clinical Research Centre at Northwick Park where he pursued his interests in HIV pathogenesis and the potential of Thalidomide to treat chronic disease. His suggestion that analogues of Thalidomide could lead to enhancement of the therapeutic activity and reduction of the side effects was taken up by David Stirling of Celgene and this partnership led to the licensing of Revlimid (Lenalidomide) and Pomalidomide (Pomalyst) for myeloma and lymphoma. He was awarded the Joshua Lederberg prize in 2011 in recognition of this work.
Since 1991, he has been Professor of Oncology at St. George's University of London. During this time, he has focused on the immunotherapy of cancer, and has conducted numerous clinical trials involving a variety of vaccines and immunotherapy. Since 2001, he has been the Principal of the Cancer Vaccine Institute, currently focusing on the revival of the Mycobacterium-based vaccines that were dropped by SR Pharma and now resurrected by Immodulon.
He is on numerous scientific advisory boards involving the development of vaccines and immunotherapy, including Celgene, Immodulon, Curevac, Bionor Pharma, and LDN Pharma. He was Chief Investigator of a randomised clinical trial in patients with metastatic panceratic cancer for Immodulon (IMM-101) and Gemcitabine versus Gemcitabine alone, which has shown a significant survival advantage for the IMM-101 combination with no significant toxicities. (Dalgleish et al., BJC 2016). In addition, his observations that Revlimid is co-stimulatory when given with vaccines has been confirmed in a randomised study of a therapeutic vaccine for HIV, where it significantly increased the CD4 counts which have not responded to HAART or the vaccine alone.